388P - ERCC1 expression in metastatic triple negative breast cancer patients treated with platinum-based chemotherapy

Date 27 September 2014
Event ESMO 2014
Session Poster Display session
Topics Cytotoxic agents
Translational Research
Breast Cancer
Basic Principles in the Management and Treatment (of cancer)
Therapy
Biological therapy
Presenter Mohamed Elbaiomy
Citation Annals of Oncology (2014) 25 (suppl_4): iv116-iv136. 10.1093/annonc/mdu329
Authors M.A. Elbaiomy1, M.I. El Zaafarany2, W.F. Elkashef3
  • 1Medical Oncology, Oncology Center, mansoura - Dakahlia/EG
  • 2Medical Oncology, Oncology Center, Mansoura - Dakahlia/EG
  • 3Pathology, Oncology Center, Mansoura - Dakahlia/EG

Abstract

Aim

To assess the impact of ERCC1 expression on PFS, OS and response rate in metastatic triple negative breast cancer patients treated with platinum-based chemotherapy.

Methods

From June 2012 to November 2013, 52 metastatic triple negative breast cancer patients were enrolled. ERCC1 protein expression was detected from pretreatment biopsies by Immunohistochemistry. All patients received cisplatin plus paclitaxel. The primary end point was the impact of ERCC1 expression on PFS and OS.

Results

34 patients (65.4%) showed positive ERCC1 expression while 18 patients (34.6%) showed negative ERCC1 expression. Positive ERCC1 expression was associated with short PFS (median, 5 months vs. 7 months; P = 0.043). Positive ERCC1 expression was associated with short OS (median, 9 months vs. 11 months; P = 0.033). Also, positive ERCC1 expression was associated with poor response to cisplatin based chemotherapy (P = 0.046).

Conclusions

This prospective study further validates ERCC1 as a reliable biomarker for customized chemotherapy in metastatic triple negative breast cancer patients and shows that high expression of ERCC1 was significantly associated with poor outcome in patients treated with platinum based chemotherapy.

Disclosure

All authors have declared no conflicts of interest.